Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843-1844)

We commend Dr Good's editorial1 for its maintenance of equipoise on the use of intravitreal bevacizumab (IVB) in retinopathy of prematurity (ROP). We would like to expand on his discussion regarding the potential neurodevelopmental consequences of vascular endothelial growth factor inhibition, over which there has been much concern.2 The strong opinions expressed in other editorials and positions taken in public meetings raise the suspicion that confirmation bias may lead to widespread acceptance of retrospective studies whose interpretations qualify as hypothesis generators.

Source: Ophthalmology - September 19, 2017 Category: Opthalmology Authors: Michael P. Blair, Michael J. Shapiro, Ad Hoc Group Concerning Neurodevelopment and antiVEGF Tags: Correspondence Source Type: research